Ola Vedin

3.2k total citations
45 papers, 2.0k citations indexed

About

Ola Vedin is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Ola Vedin has authored 45 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Cardiology and Cardiovascular Medicine, 15 papers in Endocrinology, Diabetes and Metabolism and 11 papers in Surgery. Recurrent topics in Ola Vedin's work include Cardiovascular Function and Risk Factors (14 papers), Diabetes Treatment and Management (14 papers) and Heart Failure Treatment and Management (13 papers). Ola Vedin is often cited by papers focused on Cardiovascular Function and Risk Factors (14 papers), Diabetes Treatment and Management (14 papers) and Heart Failure Treatment and Management (13 papers). Ola Vedin collaborates with scholars based in Sweden, United States and Germany. Ola Vedin's co-authors include Ulf Dahlström, Gianluigi Savarese, Lars H. Lund, Carolyn S.P. Lam, Giuseppe Rosano, Tiew‐Hwa Katherine Teng, Lina Benson, Angela S. Koh, Wan Ting Tay and Emil Hagström and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and Diabetes.

In The Last Decade

Ola Vedin

40 papers receiving 2.0k citations

Peers

Ola Vedin

CCM

EDM

PHYSI

SURGE

Mar Domingo Spain

Savvas Toumanidis Greece

Kei Tsumura Japan

Yukihito Sato Japan

Alice Bonomi Italy

Ricardo Fontes‐Carvalho Portugal

Shinji Makita Japan

Rong Tang United States

Timothy J. Vittorio United States

Takashi Kohno Japan

Mar Domingo Spain

Ola Vedin

1.6k ×1.3

CCM

134 ×0.3

184 ×0.5

EDM

273 ×1.0

PHYSI

287 ×1.1

SURGE

Citations per year, relative to Ola Vedin Ola Vedin (= 1×) peers Mar Domingo

Countries citing papers authored by Ola Vedin

Since Specialization

Citations

This map shows the geographic impact of Ola Vedin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ola Vedin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ola Vedin more than expected).

Fields of papers citing papers by Ola Vedin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ola Vedin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ola Vedin. The network helps show where Ola Vedin may publish in the future.

Co-authorship network of co-authors of Ola Vedin

This figure shows the co-authorship network connecting the top 25 collaborators of Ola Vedin. A scholar is included among the top collaborators of Ola Vedin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ola Vedin. Ola Vedin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Siddiqi, Tariq Jamal, Stefan D. Anker, Gerasimos Filippatos, et al.. (2023). Health Status Across Major Subgroups of Patients with Heart Failure and Preserved Ejection Fraction. European Journal of Heart Failure. 25(9). 1623–1631. 10 indexed citations

Khan, Muhammad Shahzeb, Stefan D. Anker, Gerasimos Filippatos, et al.. (2023). Vascular Disease Burden, Outcomes and Benefits with Empagliflozin in Heart Failure: Insights From the EMPEROR-Reduced Trial. Journal of Cardiac Failure. 29(10). 1345–1354. 1 indexed citations

Harrington, Josephine, Jacob A. Udell, W. Schuyler Jones, et al.. (2022). Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial. American Heart Journal. 253. 86–98. 45 indexed citations

Vedin, Ola, Sergey Rodin, Oscar E. Simonson, et al.. (2022). Patients With Bicuspid Aortic Stenosis Demonstrate Adverse Left Ventricular Remodeling and Impaired Cardiac Function Before Surgery With Increased Risk of Postoperative Heart Failure. Circulation. 146(17). 1310–1322. 13 indexed citations

Desai, Rishi, Robert J. Glynn, Brendan M. Everett, et al.. (2022). Comparative effectiveness of Empagliflozin in reducing the burden of recurrent cardiovascular hospitalizations among older adults with diabetes in routine clinical care. American Heart Journal. 254. 203–215. 12 indexed citations

Anker, Stefan D., Leif Erik Sander, David Fitchett, et al.. (2022). Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease. Diabetes Research and Clinical Practice. 186. 109837–109837. 7 indexed citations

Savarese, Gianluigi, Alicia Uijl, Lars H. Lund, et al.. (2021). Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial. Journal of Cardiac Failure. 27(8). 888–895. 18 indexed citations

Rosengren, Sara, Tor Skibsted Clemmensen, Lars Poulsen Tolbod, et al.. (2020). Diagnostic Accuracy of [11C]PIB Positron Emission Tomography for Detection of Cardiac Amyloidosis. JACC. Cardiovascular imaging. 13(6). 1337–1347. 60 indexed citations

Fu, Michael, Ola Vedin, Bodil Svennblad, et al.. (2020). Implementation of Sacubitril/Valsartan in Sweden: Clinical Characteristics, Titration Patterns, and Determinants. ESC Heart Failure. 7(6). 3633–3643. 21 indexed citations

10.

Butler, Javed, Stefan D. Anker, Gerasimos Filippatos, et al.. (2020). Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. European Heart Journal. 42(13). 1203–1212. 110 indexed citations

11.

Savarese, Gianluigi, Ola Vedin, Domenico D’Amario, et al.. (2019). Prevalence and Prognostic Implications of Longitudinal Ejection Fraction Change in Heart Failure. JACC Heart Failure. 7(4). 306–317. 142 indexed citations

12.

Savarese, Gianluigi, Nicola Orsini, Camilla Hage, et al.. (2018). Utilizing NT-proBNP for Eligibility and Enrichment in Trials in HFpEF, HFmrEF, and HFrEF. JACC Heart Failure. 6(3). 246–256. 54 indexed citations

13.

Savarese, Gianluigi, Nicola Orsini, Camilla Hage, et al.. (2018). Associations With and Prognostic and Discriminatory Role of N-Terminal Pro–B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction. Journal of Cardiac Failure. 24(6). 365–374. 31 indexed citations

14.

Kero, Tanja, Jens Sørensen, Gunnar Antoni, et al.. (2018). Quantification of 11C-PIB kinetics in cardiac amyloidosis. Journal of Nuclear Cardiology. 27(3). 774–784. 16 indexed citations

15.

Koh, Angela S., Wan Ting Tay, Tiew‐Hwa Katherine Teng, et al.. (2017). A Comprehensive Population-Based Characterization of Heart Failure with Mid-Range Ejection Fraction. European Journal of Heart Failure. 19(12). 1624–1634. 211 indexed citations

16.

Stewart, Ralph, Claes Held, Nermin Hadziosmanovic, et al.. (2017). Physical Activity and Mortality in Patients With Stable Coronary Heart Disease. Journal of the American College of Cardiology. 70(14). 1689–1700. 191 indexed citations

17.

Vedin, Ola, Emil Hagström, Ollie Östlund, et al.. (2017). Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease. International Journal of Cardiology. 245. 271–276. 23 indexed citations

18.

Stewart, Ralph, Claes Held, Ola Vedin, et al.. (2013). Physical activity in patients with stable coronary heart disease: an international perspective. European Heart Journal. 34(42). 3286–3293. 70 indexed citations

19.

Vedin, Ola, Emil Hagström, Dianne Gallup, et al.. (2013). TOOTH LOSS IS HIGHLY PREVALENT AND ASSOCIATED WITH CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH CHRONIC CORONARY HEART DISEASE IN THE GLOBAL STABILITY TRIAL. Journal of the American College of Cardiology. 61(10). E1368–E1368. 2 indexed citations

20.

Antoni, Gunnar, Mark Lubberink, Sergio Estrada, et al.. (2012). In Vivo Visualization of Amyloid Deposits in the Heart with ¹¹C-PIB and PET. Journal of Nuclear Medicine. 54(2). 213–220. 188 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact